Loading company financials…
NYSE · Pharmaceutical Preparations · CIK 0001555280
$75.81
-1.98% · delayed 15 min
$32.21B market value
What this company does
Zoetis develops and makes medicines. It took in $9.47B last year, which makes it a mid-sized company. Of every dollar it sells, about 28 cents is left as profit.
Financial health
Strong finances across the board.
From Zoetis Inc.'s FY2025 annual filing · share price scored separately
Every check behind the three models, and what each one tests
of 9 checks passed
Measured against FY2024, from the 10-K
Improved: +7.5%
$2.49B to $2.67B
Improved: +1.2 pts
70.6% to 71.8%
Improved: +1.4 pts
26.9% to
It makes a profit rather than burning through money.
$2.67B earned last year
Day-to-day operations generate real cash, not just accounting profit.
$2.90B cash from operations
A widely used bankruptcy-risk model places it well clear of distress.
Altman Z 4.56
Nothing in the filings stands out as a concern.
Filter by minute, hour, day or week
Loading price history…
Expectations
Not from the filings — what other people are betting on, and what the price already assumes.
The growth rate someone buying today is paying for, against what the company has delivered
At today's price, the market is paying for free cash flow to grow by about 4% a year for the next 10 years. Over the last 10 years it grew by about 18% a year.
The essentials
Each answered from the filings, with the numbers behind it.
Yes. It keeps about 28 cents of every dollar of sales as profit, earning $2.67B last year.
What it earns, what it keeps, and what it costs to run — all from the same filing
Income
This company pays no dividend. It keeps its profits and reinvests them in the business instead, so any return would have to come from the share price.
Figures from the FY2025 annual filing
Last year it earned $2.67B and generated $2.90B of cash from operations.
Reported annual figures
Insider activity, ownership stakes and what's coming — straight from EDGAR, before any article is written about it
Estimated from how often this has happened before, not a confirmed date.
Not investment advice, and not a signal to act on by itself — a filing says what happened, not why, and insiders trade for ordinary reasons having nothing to do with where they think the company is headed.
Go deeper
Every figure above traces back to one of these filings.
Straight from SEC EDGAR — the original source for every figure above
| Filing | Filed | Covers to |
|---|---|---|
| Major event announcement(8-K) | 2026-08-06 | 2026-08-06 |
| Quarterly report(10-Q) | 2026-08-06 | 2026-06-30 |
Financial figures are from ZTS's 10-K for fiscal year 2025 (period ending 2025-12-31), reported under the US GAAP taxonomy. View the source filing.
Nine yes-or-no tests of whether this year's finances improved on last year's.
4.56
In the safe zone
For this model, above 2.99 is safe and below 1.81 is distress.
Distance from bankruptcy, from a model fitted on companies that did and did not go bust. It describes a balance sheet's shape today; it does not forecast a failure.
-2.45
Below the threshold — nothing unusual flagged
Scores above -1.78 are the ones the model associates with earnings manipulation.
Screens eight accounting ratios for the pattern earnings manipulators tend to leave. A flag is a reason to read the filing closely, never evidence of wrongdoing.
Every figure above comes from the FY2025 filing as filed with the SEC.
Deteriorated: +73.2%
$5.22B to $9.04B
Improved: +16.4%
$1.99B to $2.31B
Improved: -5.3%
448.5M to 424.9M
Changed: -5.2%
$655.0M to $621.0M
2 other measures barely moved. Figures compare the two most recent annual filings — read the latest one. Nothing here reads the management commentary, which is where a company explains its own numbers.
Discounted at 8%–10% a year, with growth settling to 2.5% after 10 years. Those rates are ordinary choices, not measurements: across that range the assumed growth works out between 1% and 6%. This describes what the price implies — it is not a forecast, and not a view on whether the price is right.
Measured on and published about a week later — this is a fortnightly snapshot, not a live position.
About 3.9% of this company's shares have been borrowed and sold by people expecting to buy them back cheaper. That is a bet the price falls. Those people can be wrong, and when a heavily shorted share rises they have to buy it back, which pushes it up further.
Collected by FINRA from broker-dealers twice a month. It counts positions, not intentions, and some of it is hedging rather than a directional bet against the company.
Nothing in this section is a figure this company reported about itself. These are expectations and positions — what the price implies, what analysts have published, what short sellers are betting, and what large funds held at the last count. WylthIQ reports them; it does not endorse them, does not forecast prices, and takes no view on whether any of them will turn out to be right.
Barely. Sales were roughly flat, up 2.3%.
No. At its current cash flow it could clear its debt in about 2.3 years. For every $1 it owes, it owns $1.27 in assets.
On the cheaper side. Investors pay $12.1 for every $1 of yearly profit.
Nothing unusual. Its accounting patterns look like those of companies that report earnings straightforwardly.
At a glance
| Major event announcement(8-K) | 2026-08-06 | 2026-08-06 |
| Major event announcement(8-K) | 2026-05-22 | 2026-05-20 |
| Major event announcement(8-K) | 2026-05-20 | 2026-05-20 |
| Quarterly report(10-Q) | 2026-05-07 | 2026-03-31 |
| Major event announcement(8-K) | 2026-05-07 | 2026-05-07 |
| Shareholder voting information(DEF 14A) | 2026-04-08 | 2025-12-31 |
| Annual report(10-K) | 2026-02-12 | 2025-12-31 |
| Major event announcement(8-K) | 2026-02-12 | 2026-02-12 |
| Major event announcement(8-K) | 2026-02-05 | 2026-02-05 |
| Major event announcement(8-K) | 2025-12-18 | 2025-12-15 |
| Major event announcement(8-K) | 2025-12-11 | 2025-12-11 |
| Major event announcement(8-K) | 2025-12-02 | 2025-12-02 |
| Quarterly report(10-Q) | 2025-11-04 | 2025-09-30 |
| Major event announcement(8-K) | 2025-11-04 | 2025-11-04 |
| Major event announcement(8-K) | 2025-10-28 | 2025-10-23 |
| Major event announcement(8-K) | 2025-10-09 | 2025-10-09 |
| Major event announcement(8-K) | 2025-08-27 | 2025-08-27 |
| Major event announcement(8-K) | 2025-08-18 | 2025-08-11 |
Coverage from the last 30 days
Veterinary Diagnostic Markets Report Now Available — See Exactly How IDEXX, Zoetis, Antech, Roche, and Thermo Fisher Are Positioned to Win Through 2030
Yahoo Finance ·
Is Zoetis Stock Underperforming the S&P 500?
Yahoo Finance ·
Zoetis to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
Yahoo Finance ·
Michael Burry Bought Beaten-Down Stocks And Shorted AI Favorites — Here’s How His August Bets Fared
Yahoo Finance ·
Zoetis Wins Emergency Authorization for Simparica Trio, Can It Support a Slowing U.S. Business?
Yahoo Finance ·
Zoetis Earnings Reveal a Divided Business, But Can its Pipeline Restore Growth?
Yahoo Finance ·
Zoetis (ZTS) Stock Still Looks Cheap After a 62% Slide
Yahoo Finance ·
Michael Burry is Bullish on This Beaten-Down Healthcare Stock. Time to Buy?
Yahoo Finance ·
2 Large-Cap Stocks for Long-Term Investors and 1 We Avoid
Yahoo Finance ·
The Top 5 Analyst Questions From Zoetis’s Q2 Earnings Call
Yahoo Finance ·
Zoetis (ZTS) Remains a Leader, So Why Was It Sold?
Yahoo Finance ·
Phibro Animal Health Q4 Earnings Call Highlights
Yahoo Finance ·
Primary sources and further research